Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Portal de Recerca de la Universitat Autònoma de Barcelona Inici
Ajuda i PMF
Català
Español
English
Inici
Perfils
Unitats de recerca
Projectes
Producció científica
Conjunts de dades
Tesis i Treballs supervisats
Cerca per experiència, nom o afiliació
LEVELING UP IN GB THERAPY MONITORING: TOWARDS A UNIVERSAL BIOMARKER OF IMMUNE SYSTEM ATTACK
Candiota Silveira, Ana Paula
(PI)
Cabañas Egaña, Miquel
(Col.laborador/a)
Calero Perez, Maria del Pilar
(Col.laborador/a)
Javed , Zoona
(Col.laborador/a)
Lisboa, Paulo
(Col.laborador/a)
OLIER CAPARROSO, IVAN
(Col.laborador/a)
Ortega Martorell, Sandra
(Col.laborador/a)
Arus Caralto, Carles
(Investigador/a)
GABARROS CANALS, ANDREU
(Investigador/a)
Lope Piedrafita, Silvia
(Investigador/a)
Pumarola i Batlle, Martí
(Investigador/a)
Departament de Bioquímica i de Biologia Molecular
Centre de Biotecnologia Animal i de Teràpia Gènica (CBATEG)
Medicina Animal. Models animals i cel·lulars
Departament de Medicina i Cirurgia Animals
Informació general
Fingerprint
Producció científica
(1)
Fingerprint
Explora els temes de recerca tractats en aquest projecte. Les etiquetes es generen en funció dels ajuts rebuts. Juntes formen un fingerprint únic.
Ordenar per
Ponderació
Alfabèticament
Keyphrases
Glioblastoma Therapy
100%
Glioblastoma
70%
Levelling up
50%
Treatment Monitoring
50%
System Attack
50%
Universal Biomarkers
50%
Imagen
50%
Immune System
50%
Tumor
41%
Blood-brain Barrier
41%
Nanoparticles
33%
Glioblastoma multiforme
31%
Terapia
25%
1D Convolutional Neural Network
25%
Magnetic Resonance Imaging Contrast Agents
25%
Glioma Diagnosis
25%
Nanoformulation
25%
Radical Dendrimers
25%
Metal-free
25%
Gadolinium-based Contrast Agents
25%
Platinum-based
25%
Platinum Drugs
25%
Free Radicals
25%
Therapy Response
25%
1H-MRS
24%
GL261
20%
Magnetic Resonance Imaging
18%
Radical Species
18%
Prodrug
16%
Temozolomide
16%
Platinum Complexes
16%
Datos
16%
Standard of Care
16%
Radiotherapy
16%
Anticancer Drugs
16%
Cancer Cells
16%
Chemotherapy
16%
Surgical Resection
16%
Nanomedicine
16%
Brain Tumor
14%
Ello
12%
Pacientes
12%
1-dimensional Convolutional Neural Network (1D-CNN)
12%
PROXYL
12%
Organic Radicals
12%
Imaging Acquisition
12%
Contrast Enhancement
12%
CoMoS
8%
Inteligencia Artificial
8%
Therapy Response Assessment
8%
Primary Malignant Tumors
8%
Systemic Concentration
8%
Platinum Anticancer Drugs
8%
Pt-based Drugs
8%
Therapeutic Effect
8%
Current Therapies
8%
Magnetic Resonance Spectroscopy
8%
Neurotoxicity
8%
Dismal Prognosis
8%
Intracellular Accumulation
8%
Passive Diffusion
8%
Evade
8%
Median Survival
8%
Long-term Treatment
8%
Anticancer Activity
8%
Overall Survival
8%
Malignancy
8%
Primary Brain Tumor
8%
Cancer Chemotherapy
8%
Still Face
8%
Acquired Resistance
8%
Lipophilicity
8%
Platinum(IV)
8%
Alkylating Agents
8%
Therapeutic Potential
8%
Central Nervous System
8%
Noninvasive Route
8%
Tumor Cells
8%
Systemic Toxicity
8%
Intrinsic Resistance
8%
5-year Survival
8%
Concomitant Treatment
8%
Reduced Toxicity
8%
Chemoradiotherapy
8%
Phosphorhydrazone
6%
Surface-bound Radicals
6%
Brain Tumor Tissue
6%
Toxic Metal Accumulation
6%
Non-radial
6%
Brain Cancer
6%
Selective Accumulation
6%
Imaging Approach
6%
Early Diagnosis
6%
Biological Media
6%
Water-soluble
6%
Non-invasive Method
6%
Paramagnetic Properties
6%
Magnetic Resonance Imaging Analysis
6%
Contrast Agent
6%
Base Metals
6%
Macromolecules
6%
Organic Species
6%
Brain Magnetic Resonance Imaging
6%
Blood-brain Barrier Integrity
6%
Long-term Retention
6%
Dendrimer
6%
Gadolinium Chelate
6%
High-grade Tumor
6%
High Stability
6%
Third Generation
6%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
44%
Blood Brain Barrier
40%
Nanoparticle
30%
Magnetic Resonance Imaging
27%
Free Radical
25%
Contrast Medium
25%
Nuclear Magnetic Resonance Imaging Agent
25%
Dendrimer
25%
Treatment Response
25%
Ex Vivo
25%
Gadolinium
20%
Anticarcinogen
18%
Intracranial Tumor
15%
Cancer Cell
13%
Surgery
13%
Radiation Therapy
13%
Side Effect
13%
Brain Cancer
13%
Nanomedicine
13%
Chemotherapy
13%
Temozolomide
10%
Platinum Complex
10%
Prodrug
10%
Physician
8%
Overall Survival
8%
Survival Rate
8%
Malignant Neoplasm
8%
Central Nervous System
8%
NMR Spectroscopy
8%
Cancer
5%
Tumor Cell
5%
Antiinfective Agent
5%
Antineoplastic Activity
5%
Gadolinium Chelate
5%
Therapy Effect
5%
Cancer Chemotherapy
5%
Chemoradiotherapy
5%
Early Diagnosis
5%
Non Invasive Procedure
5%
Alkylating Antineoplastic Agent
5%
Neurotoxicity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Neoplasm
50%
Blood-Brain Barrier
40%
Nanoparticle
30%
Free Radical
25%
Nuclear Magnetic Resonance Imaging Agent
25%
Dendrimer
25%
Contrast Medium
25%
Malignant Neoplasm
21%
Gadolinium
20%
Anticarcinogen
18%
Chemotherapy
18%
Intracranial Tumor
15%
Side Effect
13%
Brain Cancer
13%
Nanomedicine
13%
Platinum Complex
10%
Temozolomide
10%
Prodrug
10%
Murine
9%
Overall Survival
8%
Survival Rate
8%
Therapeutic Effect
5%
Antiinfective Agent
5%
Chemoradiation Therapy
5%
Lipophilicity
5%
Gadolinium Chelate
5%
Alkylating Agent
5%
Neurotoxicity
5%